Skip to main content

Characteristics and Drug Utilization in Dabigatran, Rivaroxaban, and Apixaban Initiators Aged 64 or Younger: A Descriptive Analysis

Basic Details
Date Posted
Status
Complete
Medical Product
apixaban
dabigatran
rivaroxaban
Description

In this analysis, we examined utilization and characteristics of non-vitamin K antagonist oral anticoagulants (NOACs) initiators (including dabigatran, rivaroxaban, and apixaban) in those between 21 - 64 years of age in the Sentinel Distributed Database (SDD). 

The study period includes data from October 19, 2010 to September 30, 2015. We distributed this request to 16 Sentinel Data Partners on January 11, 2019.

This analysis contains two reports:

  • Report 1: This report examines characteristics and utilization among NOACs initiators.
  • Report 2: This report assesses follow-up time among new NOACs initiators.
Deliverables (2)
Sentinel Modular Program Report: Characteristics and Drug Utilization in Dabigatran, Rivaroxaban, and Apixaban Initiators Aged 64 or Younger: A Descriptive Analysis, Report 1 Sentinel Modular Program Report: Characteristics and Drug Utilization in Dabigatran, Rivaroxaban, and Apixaban Initiators Aged 64 or Younger: A Descriptive Analysis, Report 2
Additional Details
FDA Center
CDER
Time Period
October 19, 2010 – September 30, 2015
Analysis Type
Descriptive
Population / Cohort
Individuals 21 to 64 years of age
Data Sources
Sentinel Distributed Database (SDD)
Related Links
Sentinel Drug Study: Eliquis (Apixaban), Pradaxa (Dabigatran), and Xarelto (Rivaroxaban) & Gastrointestinal Bleeding, Intracranial Hemorrhage, Major Extracranial Bleeding, and Thromboembolic Stroke